Thomas A. Thompson
Managing Director at Ankura Global Construction Practice
Contract and Risk Management SME
Texas, United States
About
Thomas Thompson is a Managing Director in Ankura’s Global Construction Practice. For over three decades, Mr. Thompson has delivered projects and accumulated experience across the engineering and construction industry specializing in project, contract and risk management, analysis and controls. He has extensive experience in U.S. and major international refining, LNG, chemical, on and offshore oil and gas development, pipelines and infrastructure ranging from 30 MM US$ to 10 billion US$.
Mr. Thompson has developed and managed corporate legal, consultant services and company assets through negotiations as Commercial Director for significant construction claims and additional compensation programs in excess of 1 billion US$. He has delivered major international projects with multi-national joint ventures as contractor in operational capacity. Mr. Thompson has also served as Senior Vice President of Operations and Joint Venture Managing Director for prior employers engineering, procurement and project management.
In the area of management consulting and risk management, Mr. Thompson was Vice President of Business Development Oversight serving as the most senior subject matter expert for technical and commercial risk oversight for all major projects, mergers and acquisition related transactions for a Fortune 200 Company reporting to the Executive Review Committee (Corporate Officers). Before working in Business Development Oversight Tom was assigned by Parent Company CEO as Corporate Director of Risk Assessment evaluating prospective commercial and operational risk position of all major fixed price transactions in progress prior to company IPO and developed indemnification positions.
Panelist
COVID-19 Project Recovery- Risk Panel Discussion
The projects risk panel discussion will be centered around intelligent risk management best practices in consideration of disruptive events such as COVID-19.